About Interleukin-1 alpha
Interleukin-1 alpha (IL1A) is a protein
from Homo sapiens identified by UniProt accession
P01583, 271 residues long.
MolForge cross-references it against 0 known binders and
1,164 disease associations.
Target properties
| Protein name | Interleukin-1 alpha |
|---|
| UniProt accession | P01583 |
|---|
| Gene | IL1A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 271 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (1164)
Diseases linked to this target (Open Targets).
- endometriosis · score 0.34
- dysmenorrheic pain measurement · score 0.32
- hidradenitis suppurativa · score 0.30
- neoplasm · score 0.29
- colorectal adenocarcinoma · score 0.26
- colorectal cancer · score 0.26
- quality of life during menstruation measurement · score 0.26
- breast adenocarcinoma · score 0.25
- glioblastoma multiforme · score 0.24
- head and neck squamous cell carcinoma · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P01583-F1 | alphafold | PREDICTED | 73.92 | — |
Amino-acid sequence (271 residues)
MAKVPDMFED LKNCYSENEE DSSSIDHLSL NQKSFYHVSY GPLHEGCMDQ SVSLSISETS KTSKLTFKES MVVVATNGKV LKKRRLSLSQ SITDDDLEAI ANDSEEEIIK PRSAPFSFLS NVKYNFMRII KYEFILNDAL NQSIIRANDQ YLTAAALHNL DEAVKFDMGA YKSSKDDAKI TVILRISKTQ LYVTAQDEDQ PVLLKEMPEI PKTITGSETN LLFFWETHGT KNYFTSVAHP NLFIATKQDY WVCLAGGPPS ITDFQILENQ A
Explore Interleukin-1 alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets